Clinical trials: Nonsmall Cell Lung Cancer Stage III
Lung Cancer
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280150
- Testing
- bevacizumab, carboplatin, erlotinib hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body (metastatic) on single agent…
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06731270
- Testing
- Atezolizumab, Biospecimen Collection, Cemiplimab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have refractory or…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00020202
- Testing
- FR901228
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Lung Neoplasms
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy.
- Trial name
- NCT01770418
- Testing
- Radiation with Concurrent Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- Proton Collaborative Group
Locally Advanced Squamous Non-small Cell Lung Cancer
Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy
This study is a prospective, single arm, single center open clinical study aimed at evaluating the efficacy and safety of recombinant human endostatin and envafolimab combined with synchronal radiochemotherapy in patients with…
- Trial name
- NCT06279754
- Testing
- Recombinant Human Endostatin Injection
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xinxiang Medical College
Lung Cancer
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells.
- Trial name
- NCT00589056
- Testing
- cisplatin, etoposide, nelfinavir mesylate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112710
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,350 people
- Sponsor
- University Hospital Birmingham
Lung Cancer, Carcinoma, Non-Small-Cell Lung
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
The purpose of this study is to assess how well this particular combination of chemotherapy, radiation and surgery works to help people with locally advanced lung cancer, how well PET scans indicates whether someone has responded…
- Trial name
- NCT00238615
- Testing
- Docetaxel, Carboplatin, Radiation therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Non-Small Cell Lung Cancer Stage III
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not…
- Trial name
- NCT03728556
- Testing
- CS1001 monoclonal antibody
- Where
- China
- Volunteers
- 381 people
- Sponsor
- CStone Pharmaceuticals
Non-small Cell Lung Cancer Stage III
Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab
Lung cancer presents a significant treatment challenge, particularly in the heterogeneous stage III NSCLC patient population. While chemotherapy combined with high-dose radiotherapy (60 Gy in 30 fractions of 2 Gy once daily) is…
- Trial name
- CROWD (NCT06908070)
- Testing
- Consolidation durvalumab
- Where
- Netherlands
- Volunteers
- 38 people
- Sponsor
- Idris Bahce
Stage III Non-small Cell Lung Cancer, Unresectable
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents.
- Trial name
- COAST (NCT03822351)
- Testing
- Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 189 people
- Sponsor
- MedImmune LLC
Lung Cancer
Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin and vinorelbine are more effective with or without tirapazamine in treating…
- Trial name
- NCT00017459
- Testing
- cisplatin, tirapazamine, vinorelbine tartrate
- Where
- 42 sites in United States
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor…
- Trial name
- NCT06080776
- Testing
- SH-1028 tablets
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Lung Cancer
Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
It is apparent that local control for Non-small Cell Lung Cancer (NSCLC) remains a significant problem. Conventional radiation therapy techniques have limitations for the dose that can be delivered to a chest tumor mass due to…
- Trial name
- NCT01657617
- Testing
- Boost Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ronald McGarry
Efficacy and Safety
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC
Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens.
- Trial name
- NCT04284215
- Testing
- Albumin paclitaxel combined with cisplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Guizhou Medical University
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00287989
- Testing
- Carboplatin, erlotinib hydrochloride, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer
Phase I trial to study the effectiveness of LMB-9 immunotoxin in treating patients who have advanced colon, breast, non-small cell lung, bladder, pancreatic, or ovarian cancer.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00005858
- Testing
- LMB-9 immunotoxin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Maryland, Baltimore
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
This is an open label, prospective, single center Phase II clinical study. Intended to evaluate the main pathological response rate (MPR) and safety of stereotactic immunosensitized radiotherapy combined with Evoximab…
- Trial name
- NCT06391008
- Testing
- Stereotactic radiotherapy, Evoximab, Pemetrexed
- Volunteers
- 44 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NSCLC
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC
The goal of this clinical trial is to compare the efficacy and safety of induction Benmelstobart plus Anlotinib and chemotherapy followed by concurrent chemoradiotherapy (CCRT) and subsequent Benmelstobart maintenance versus CCRT…
- Trial name
- NCT07643350
- Testing
- Benmelstobart, benmelstobart combined with chemotherapy and anlotinib
- Where
- China
- Volunteers
- 152 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Lung Cancer
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003158
- Testing
- carboplatin, etoposide, paclitaxel
- Where
- 86 sites in United States
- Volunteers
- 96 people
- Sponsor
- SWOG Cancer Research Network